These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22281545)

  • 1. Primary aldosteronism: are we missing the wood for the trees?
    Funder JW
    Horm Metab Res; 2012 Mar; 44(3):251-3. PubMed ID: 22281545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary aldosteronism: who should be screened?
    Monticone S; Viola A; Tizzani D; Crudo V; Burrello J; Galmozzi M; Veglio F; Mulatero P
    Horm Metab Res; 2012 Mar; 44(3):163-9. PubMed ID: 22120135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism.
    Somlóová Z; Widimský J; Rosa J; Wichterle D; Strauch B; Petrák O; Zelinka T; Vlková J; Masek M; Dvoráková J; Holaj R
    J Hum Hypertens; 2010 Oct; 24(10):625-30. PubMed ID: 20574447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
    Shibata H; Itoh H
    Am J Hypertens; 2012 May; 25(5):514-23. PubMed ID: 22258336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism.
    Catena C; Colussi G; Di Fabio A; Valeri M; Marzano L; Uzzau A; Sechi LA
    Horm Metab Res; 2010 Jun; 42(6):440-5. PubMed ID: 20119883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
    Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
    Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants.
    Ronconi V; Turchi F; Rilli S; Di Mattia D; Agostinelli L; Boscaro M; Giacchetti G
    Nutr Metab Cardiovasc Dis; 2010 Feb; 20(2):93-100. PubMed ID: 19481913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension.
    Strauch B; Petrák O; Wichterle D; Zelinka T; Holaj R; Widimský J
    Am J Hypertens; 2006 Sep; 19(9):909-14. PubMed ID: 16942932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistant hypertension and aldosterone: an update.
    Clark D; Ahmed MI; Calhoun DA
    Can J Cardiol; 2012 May; 28(3):318-25. PubMed ID: 22521297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone and refractory hypertension: a prospective cohort study.
    Sartori M; Calò LA; Mascagna V; Realdi A; Macchini L; Ciccariello L; De Toni R; Cattelan F; Pessina AC; Semplicini A
    Am J Hypertens; 2006 Apr; 19(4):373-9; discussion 380. PubMed ID: 16580572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone and Mineralocorticoid Receptors-Physiology and Pathophysiology.
    Funder JW
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
    Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
    Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting and treating primary aldosteronism: primary aldosteronism.
    Mantero F; Mattarello MJ; Albiger NM
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):171-4. PubMed ID: 17427105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension.
    Turchi F; Ronconi V; di Tizio V; Boscaro M; Giacchetti G
    Am J Hypertens; 2011 Dec; 24(12):1274-9. PubMed ID: 21850059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism.
    Maule S; Bertello C; Rabbia F; Milan A; Mulatero P; Milazzo V; Papotti G; Veglio F
    Hypertens Res; 2011 Oct; 34(10):1078-81. PubMed ID: 21677661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney impairment in primary aldosteronism.
    Wu VC; Yang SY; Lin JW; Cheng BW; Kuo CC; Tsai CT; Chu TS; Huang KH; Wang SM; Lin YH; Chiang CK; Chang HW; Lin CY; Lin LY; Chiu JS; Hu FC; Chueh SC; Ho YL; Liu KL; Lin SL; Yen RF; Wu KD;
    Clin Chim Acta; 2011 Jul; 412(15-16):1319-25. PubMed ID: 21345337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.
    Sechi LA; Colussi G; Di Fabio A; Catena C
    Am J Hypertens; 2010 Dec; 23(12):1253-60. PubMed ID: 20706195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.
    Hundemer GL
    Curr Cardiol Rep; 2019 Jul; 21(9):93. PubMed ID: 31352525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.